ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV, as well as treatments for inflammatory/autoimmune diseases and cancer, today reported that it has signed a EUR 20 million (USD 23.41 million) structured debt financing with Kreos Capital.
Didier Blondel, Chief Financial Officer of Abivax, said: “This agreement with Kreos Capital is an important part of our financial strategy that allows us to limit dilution and to protect shareholder value while significantly extending our funding reach. It will also provide additional resources needed to complete phase 2b studies of ABX464 in both HIV and in Ulcerative Colitis, as well as the phase 1/2 study of ABX196 in hepatocellular carcinoma.”
